Vorozole: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 02:58, 24 October 2011 editCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified and watched fields - updated 'ChEBI_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report errors or bugs)← Previous edit		Latest revision as of 17:42, 7 September 2024 edit undoJWBE (talk \| contribs)Extended confirmed users10,129 edits removed Category:Chloroarenes; added Category:4-Chlorophenyl compounds using HotCat
(39 intermediate revisions by 26 users not shown)
Line 1:		Line 1:
			{{Short description\|Chemical compound}}
			{{cs1 config\|name-list-style=vanc}}
	{{Drugbox		{{Drugbox
	\| Verifiedfields = changed		\| Verifiedfields = changed
	\| Watchedfields = changed		\| Watchedfields = changed
	\| verifiedrevid = ~~409110490~~		\| verifiedrevid = 470631940
	\| IUPAC_name = 6-~~-<br>~~-1-methylbenzotriazole		\| IUPAC_name = 6--1-methylbenzotriazole
	\| image = Vorozole.svg		\| image = Vorozole.svg

	<!--Clinical data-->		<!--Clinical data-->
	\| tradename =		\| tradename =
	\| pregnancy_category =		\| pregnancy_category =
	\| legal_status =		\| legal_status =
	\| routes_of_administration =		\| routes_of_administration =

	<!--Pharmacokinetic data-->		<!--Pharmacokinetic data-->
Line 16:		Line 18:
	\| metabolism = Hepatic		\| metabolism = Hepatic
	\| elimination_half-life = 8 hours		\| elimination_half-life = 8 hours
	\| excretion =		\| excretion =

	<!--Identifiers-->		<!--Identifiers-->
	\| CAS_number_Ref = {{cascite\|~~correct~~\|??}}		\| CAS_number_Ref = {{cascite\|changed\|??}}
	\| CAS_number = ~~118949~~-22-7		\| CAS_number = 129731-10-8
	\| ATC_prefix = L02		\| ATC_prefix = L02
	\| ATC_suffix = BG05		\| ATC_suffix = BG05
Line 27:		Line 29:
	\| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}}		\| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}}
	\| ChemSpiderID = 5293402		\| ChemSpiderID = 5293402
	\| UNII_Ref = {{fdacite\|~~changed~~\|FDA}}		\| UNII_Ref = {{fdacite\|correct\|FDA}}
	\| UNII = 1E2S9YXV2A		\| UNII = 1E2S9YXV2A
	\| KEGG_Ref = {{keggcite\|correct\|kegg}}		\| KEGG_Ref = {{keggcite\|correct\|kegg}}
	\| KEGG = D03786		\| KEGG = D03786
	\| ChEMBL_Ref = {{ebicite\|~~changed~~\|EBI}}		\| ChEMBL_Ref = {{ebicite\|correct\|EBI}}
	\| ChEMBL = 224060		\| ChEMBL = 224060
			\| synonyms = R-76713; Rizivor

	<!--Chemical data-->		<!--Chemical data-->
	\| C=16 \| H=13 \| Cl=1 \| N=6		\| C=16 \| H=13 \| Cl=1 \| N=6
		⚫	\| SMILES = Clc1ccc(cc1)(c2ccc3nnn(c3c2)C)n4ncnc4
	\| molecular_weight = 324.768 g/mol
⚫	\| ~~smiles~~ = Clc1ccc(cc1)(c2ccc3nnn(c3c2)C)n4ncnc4
	\| InChI = 1/C16H13ClN6/c1-22-15-8-12(4-7-14(15)20-21-22)16(23-10-18-9-19-23)11-2-5-13(17)6-3-11/h2-10,16H,1H3/t16-/m0/s1
	\| InChIKey = XLMPPFTZALNBFS-INIZCTEOBI
	\| StdInChI_Ref = {{stdinchicite\|correct\|chemspider}}
	\| StdInChI = 1S/C19H23NO4S/c1-4-14(2)15-8-10-17(11-9-15)24-13-19(21)20-16-6-5-7-18(12-16)25(3,22)23/h5-12,14H,4,13H2,1-3H3,(H,20,21)/t14-/m0/s1
	\| StdInChIKey_Ref = {{stdinchicite\|correct\|chemspider}}
	\| StdInChIKey = CEFCZGGDYKYFJV-AWEZNQCLSA-N
	}}		}}
	'''Vorozole''' is an ] based competitive inhibitor of the ] enzyme. It underwent clinical testing for evaluation for use as an ] agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent ] and research instead focused on the other third generation ] ], ] and ].

	It is ~~selective~~.<ref name="pmid9797019">{{cite journal \|~~author~~=Goss PE \|title=Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor \|journal=Breast Cancer ~~Res.~~ ~~Treat.~~ \|volume=~~Suppl~~ 1 \|~~issue=~~ \|pages=~~S59–65~~; discussion ~~S73–7~~ \|~~series=49~~ \|year=1998 \|pmid=9797019 \|doi= \|url=http://www.kluweronline.com/art.pdf?issn=0167-6806&volume=49%20Suppl%201&page=S59}}</ref>		'''Vorozole''' (developmental code name '''R-76713'''; former tentative brand name '''Rizivor''') is a ] based ] of the ] enzyme. It underwent clinical testing for evaluation for use as an ] agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent ] and research instead focused on the other third generation ] ], ] and ].<ref name="pmid9797019">{{cite journal \| vauthors = Goss PE \| title = Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor \| journal = Breast Cancer Research and Treatment \| volume = 49 \| pages = S59-65; discussion S73-7 \| year = 1998 \| pmid = 9797019 \| doi = 10.1023/a:1006052923468 \| url = http://www.kluweronline.com/art.pdf?issn=0167-6806&volume=49%20Suppl%201&page=S59 \| series = 49 \| issue = Suppl 1 \| s2cid = 28231447 }}</ref>

	==~~Chemistry~~==		== References ==
			{{Reflist}}
	]

	Prous, J.; Grant, J.; Castaner, J.; Drugs Future 1994, 457.

	==References==
	{{reflist}}
	{{Sex hormones}}
	]		]
	]		]
			]
	]		]
	]


	{{~~antineoplastic~~-drug-stub}}		{{Antineoplastic-drug-stub}}

Latest revision as of 17:42, 7 September 2024

Chemical compound

Pharmaceutical compound

Vorozole
Clinical data

Other names	R-76713; Rizivor
ATC code	L02BG05 (WHO)
Pharmacokinetic data
Bioavailability	Very high
Metabolism	Hepatic
Elimination half-life	8 hours
Identifiers
IUPAC name 6--1-methylbenzotriazole
CAS Number	129731-10-8
PubChem CID	6918191
ChemSpider	5293402
UNII	1E2S9YXV2A
KEGG	D03786
ChEMBL	ChEMBL224060
CompTox Dashboard (EPA)	DTXSID20156230
Chemical and physical data
Formula	C₁₆H₁₃ClN₆
Molar mass	324.77 g·mol
3D model (JSmol)	Interactive image
SMILES Clc1ccc(cc1)(c2ccc3nnn(c3c2)C)n4ncnc4
(what is this?) (verify)

Vorozole (developmental code name R-76713; former tentative brand name Rizivor) is a triazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.

References

Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Research and Treatment. 49. 49 (Suppl 1): S59-65, discussion S73-7. doi:10.1023/a:1006052923468. PMID 9797019. S2CID 28231447.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: